Rafferty Asset Management’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
Other funds holding ALLO
Rafferty Asset Management's ALLO Position: Q3 2026 in Review
Rafferty Asset Management increased its Allogene Therapeutics (ALLO) stake by 19% in Q3 2026, buying an estimated $122K and bringing the position to 401,856 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #842.
Rafferty Asset Management first reported a position in ALLO in Q1 2019 and has held it in 26 quarters since. The position peaked at $5.17M in Q1 2022. 198 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.
- Rafferty Asset Management held 401,856 shares of Allogene Therapeutics worth $643K as of Q3 2026.
- Rafferty Asset Management bought 64,321 Allogene Therapeutics shares in Q3 2026, an estimated $122K.
- Allogene Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #842 holding.
- Rafferty Asset Management first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 26 quarters since.
- Rafferty Asset Management's Allogene Therapeutics position peaked at $5.17M in Q1 2022.
- 198 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.
Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.